Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sumatriptan + naproxen sodium is a fixed-dose combination oral medication used for the acute treatment of migraine attacks with or without aura in adults and pediatric patients 12 years of age and older. It combines two active ingredients: - Sumatriptan, a selective serotonin (5-HT) 1b/1d receptor agonist (triptan), which works by causing vasoconstriction of cranial blood vessels and inhibiting pro-inflammatory neuropeptide release. - Naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID) from the arylacetic acid group, which reduces inflammation by inhibiting cyclooxygenase enzymes involved in prostaglandin synthesis. The combination provides greater initial and sustained pain relief compared to either agent alone. It is not indicated for migraine prevention or cluster headaches[1][3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sumatriptan + naproxen sodium.